Last reviewed · How we verify

Artesunate/mefloquine (AS/MQ)

Armed Forces Research Institute of Medical Sciences, Thailand · FDA-approved active Small molecule

Artesunate/mefloquine (AS/MQ) is a Antimalarial combination Small molecule drug developed by Armed Forces Research Institute of Medical Sciences, Thailand. It is currently FDA-approved for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae. Also known as: Mequin.

Artesunate and mefloquine are antimalarial agents that work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while mefloquine disrupts parasite membrane function and metabolism.

Artesunate and mefloquine are antimalarial agents that work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while mefloquine disrupts parasite membrane function and metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

At a glance

Generic nameArtesunate/mefloquine (AS/MQ)
Also known asMequin
SponsorArmed Forces Research Institute of Medical Sciences, Thailand
Drug classAntimalarial combination
TargetPlasmodium falciparum (parasite); artesunate targets heme-dependent pathways; mefloquine targets parasite membrane and heme detoxification
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Artesunate, a semi-synthetic artemisinin derivative, is activated by heme iron in parasites to form reactive oxygen species that cause oxidative damage to parasite proteins and nucleic acids. Mefloquine is a quinoline antimalarial that concentrates in the parasite's food vacuole and interferes with heme detoxification and membrane integrity. The combination provides rapid parasite clearance (artesunate) with extended post-treatment suppression (mefloquine), reducing recrudescence and transmission.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artesunate/mefloquine (AS/MQ)

What is Artesunate/mefloquine (AS/MQ)?

Artesunate/mefloquine (AS/MQ) is a Antimalarial combination drug developed by Armed Forces Research Institute of Medical Sciences, Thailand, indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

How does Artesunate/mefloquine (AS/MQ) work?

Artesunate and mefloquine are antimalarial agents that work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while mefloquine disrupts parasite membrane function and metabolism.

What is Artesunate/mefloquine (AS/MQ) used for?

Artesunate/mefloquine (AS/MQ) is indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

Who makes Artesunate/mefloquine (AS/MQ)?

Artesunate/mefloquine (AS/MQ) is developed and marketed by Armed Forces Research Institute of Medical Sciences, Thailand (see full Armed Forces Research Institute of Medical Sciences, Thailand pipeline at /company/armed-forces-research-institute-of-medical-sciences-thailand).

Is Artesunate/mefloquine (AS/MQ) also known as anything else?

Artesunate/mefloquine (AS/MQ) is also known as Mequin.

What drug class is Artesunate/mefloquine (AS/MQ) in?

Artesunate/mefloquine (AS/MQ) belongs to the Antimalarial combination class. See all Antimalarial combination drugs at /class/antimalarial-combination.

What development phase is Artesunate/mefloquine (AS/MQ) in?

Artesunate/mefloquine (AS/MQ) is FDA-approved (marketed).

What are the side effects of Artesunate/mefloquine (AS/MQ)?

Common side effects of Artesunate/mefloquine (AS/MQ) include Nausea and vomiting, Dizziness and vertigo, Neuropsychiatric effects (anxiety, insomnia, nightmares), Abdominal pain, Headache, Cardiac arrhythmias (rare).

What does Artesunate/mefloquine (AS/MQ) target?

Artesunate/mefloquine (AS/MQ) targets Plasmodium falciparum (parasite); artesunate targets heme-dependent pathways; mefloquine targets parasite membrane and heme detoxification and is a Antimalarial combination.

Related